Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial
JMIR Dermatology · 2024-03-11 · 7 · e49965
DOI: 10.2196/49965 ↗At a glance
Randomisierte kontrollierte Studie in JMIR Dermatology, published online on 2024-03-11. Written by Isaac Weber and 12 co-authors. Institution: Mercy Hopsital St. Louis, St. Louis, MO, United States. Cited 8 times so far (Crossref); 24 references. The full text is freely available in PubMed Central. Funded by: NIAMS NIH HHS, NCATS NIH HHS.
Abstract (original language)
Background
Seborrheic dermatitis (SD) affects 18.6%-59% of persons with Parkinson disease (PD), and recent studies provide evidence that oral cannabidiol (CBD) therapy could reduce sebum production in addition to improving motor and psychiatric symptoms in PD. Therefore, oral CBD could be useful for improving symptoms of both commonly co-occurring conditions.
Objective
This study investigates whether oral CBD therapy is associated with a decrease in SD severity in PD.
Methods
Facial photographs were collected as a component of a randomized (1:1 CBD vs placebo), parallel, double-blind, placebo-controlled trial assessing the efficacy of a short-term 2.5 mg per kg per day oral sesame solution CBD-rich cannabis extract (formulated to 100 mg/mL CBD and 3.3 mg/mL THC) for reducing motor symptoms in PD. Participants took 1.25 mg per kg per day each morning for 4 ±1 days and then twice daily for 10 ±4 days. Reviewers analyzed the photographs independently and provided a severity ranking based on the Seborrheic Dermatitis Area and Severity Index (SEDASI) scale. Baseline demographic and disease characteristics, as well as posttreatment SEDASI averages and the presence of SD, were analyzed with 2-tailed t tests and Pearson χ2 tests. SEDASI was analyzed with longitudinal regression, and SD was analyzed with generalized estimating equations.
Results
A total of 27 participants received a placebo and 26 received CBD for 16 days. SD severity was low in both groups at baseline, and there was no treatment effect. The risk ratio for patients receiving CBD, post versus pre, was 0.69 (95% CI 0.41-1.18; P=.15), compared to 1.20 (95% CI 0.88-1.65; P=.26) for the patients receiving the placebo. The within-group pre-post change was not statistically significant for either group, but they differed from each other (P=.07) because there was an estimated improvement for the CBD group and an estimated worsening for the placebo group.
Conclusions
This study does not provide solid evidence that oral CBD therapy reduces the presence of SD among patients with PD. While this study was sufficiently powered to detect the primary outcome (efficacy of CBD on PD motor symptoms), it was underpowered for the secondary outcomes of detecting changes in the presence and severity of SD. Multiple mechanisms exist through which CBD can exert beneficial effects on SD pathogenesis. Larger studies, including participants with increased disease severity and longer treatment periods, may better elucidate treatment effects and are needed to determine CBD’s true efficacy for affecting SD severity. Trial Registration ClinicalTrials.gov NCT03582137; https://clinicaltrials.gov/ct2/show/NCT03582137
Subjects
Author keywords
Authors and institutions
- Mercy Hopsital St. Louis, St. Louis, MO, United States.
- Department of Dermatology, University of Colorado School of Medicine, Aurora, CO, United States.
- Department of Neurology, University of Colorado School of Medicine, Aurora, CO, United States.
- Dermatology Service, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO, United States.
- Colorado School of Public Health, Aurora, CO, United States.
ORCID profiles: Isaac Weber, Caterina Zagona-Prizio, Torunn E Sivesind, Madeline Adelman, Mindy D Szeto, Ying Liu, Stefan H Sillau, Jacquelyn Bainbridge, Jost Klawitter, Cristina Sempio, Cory A Dunnick, Maureen A Leehey, Robert P Dellavalle
Funding
- NIAMS NIH HHS
- NCATS NIH HHS
Cite
APA
Weber, I., Zagona-Prizio, C., Sivesind, T. E., Adelman, M., Szeto, M. D., Liu, Y., Sillau, S. H., Bainbridge, J., Klawitter, J., Sempio, C., Dunnick, C. A., Leehey, M. A., & Dellavalle, R. P. (2024). Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial. JMIR Dermatology, 7, e49965. https://doi.org/10.2196/49965
Vancouver
Weber I, Zagona-Prizio C, Sivesind TE, Adelman M, Szeto MD, Liu Y, et al. Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial. JMIR Dermatology. 2024;7:e49965. doi:10.2196/49965
BibTeX
@article{Weber2024,
author = {Weber, Isaac and Zagona-Prizio, Caterina and Sivesind, Torunn E and Adelman, Madeline and Szeto, Mindy D and Liu, Ying and Sillau, Stefan H and Bainbridge, Jacquelyn and Klawitter, Jost and Sempio, Cristina and Dunnick, Cory A and Leehey, Maureen A and Dellavalle, Robert P},
title = {Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial},
journal = {JMIR Dermatology},
year = {2024},
volume = {7},
pages = {e49965},
doi = {10.2196/49965}
}
EUVIMED